News

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

At the Envision Summit 2025 in San Juan, Puerto Rico, Rachel Simpson, MD, talked about new developments in glaucoma treatment and really how to tailor glaucoma treatment to the patient.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

At the Envision Summit 2025 in San Juan, Puerto Rico, Angela Zhu, MD, offered advice on cataract surgery for all ages, focusing on pediatrics.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

Advancements in drug durability and patient care are closing treatment gaps.

AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.

At the Envision Summit 2025 in San Juan, Puerto Rico, Ashley Wallace Tucker, OD, FAAO, FSLS, gave insight into advancements in keratoconus management and the importance of early detection as well as tips and advice on fitting scleral contact lens

At the Envision Summit 2025 in San Juan, Puerto Rico, Lana Rifkin, MD, gave clinicians advice on how, and when it may be most appropriate to use the new G2211 code.

At the Envision Summit 2025 in San Juan, Puerto Rico, Arjan Hura, MD, talked about EVO ICL surgery, its benefits, and how every ophthalmologist has the ability and training to conduct the surgery even if they aren't aware.

At the Envision Summit 2025 in San Juan, Puerto Rico, Nita Valikodath, MD, MS, gave insight into a challenging case of a 14-year-old boy who had trauma-related retinal detachment in his right eye, where a further macula-on retinal detachment with retinal dialysis was found in the left.

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid outcomes analysis of patients who participated in the phase 3 clinical trial PULSAR.

At the Envision Summit 2025 in San Juan, Puerto Rico, Carol Karp, MD, discussed new research presented by her fellows at the meeting on AI for the diagnosis of ocular surface tumors as well as a new "tear biopsy" for the detection of cancer.

At the Envision Summit 2025 in San Juan, Puerto Rico, Brittany Simmons, MD, discussed periorbital injuries and how they can affect the soft tissue and bones around the eye and gives insight into how clinicians should best go about treating it.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Laxmi Devisetty, MD, and Eva Kim, MD, look ahead at upcoming sessions focusing on geographic atrophy and refractive and cataract surgery at the Envision Summit 2025.

The University of Bristol research team used animal models to compare patient responses to AAV therapy, studying male and female eye cells across different age groups (young, middle-aged and older patients)

The authors conducted a retrospective, cross-sectional study in which they described a technique for estimating the melanocytic choroidal tumor thickness using only Optomap UWF images.

The research team conducted a prospective study to assess any barriers to parental compliance with vision testing in preschoolers aged 3 to 6 years.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

Researchers used data from the UK Biobank to investigate the associations between a healthy lifestyle score and retinal neurovascular health.

Routine evaluation of meibomian glands, starting in childhood, is crucial for identifying and managing this progressive disease before it leads to long-term ocular surface issues.

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways.

The study’s main outcome measures were the changes in those 2 parameters following treatment with teprotumumab.

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, rashes, and a chemical corneal burn in babies.